Table 1 Descriptive statistics of study period, context, and methodology of included studies
Study characteristic | Total (n = 19) |
|---|---|
N (%) | |
Year of publication | |
 Before 2014 | 4 (21.1%) |
 2014–2016 | 6 (31.6%) |
 2017–2019 | 9 (47.4%) |
Study design | |
 Randomized/cluster-randomized | 9 (47.4%) |
 Quasi-experimental | 5 (26.3%) |
 Before-and-after | 4 (21.1%) |
 Other non-randomized | 1 (5.3%) |
Country (n = 21) | |
 Nigeria | 9 (42.9%) |
 South Africa | 5 (23.8%) |
 Kenya | 3 (14.3%) |
 Tanzania | 1 (4.8%) |
 Uganda | 1 (4.8%) |
 Mozambique | 1 (4.8%) |
 Zambia | 1 (4.8%) |
Urban/rural setting | |
 Urban/semi-urban only | 6 (31.6%) |
 Rural only | 4 (21.1%) |
 Both urban and rural | 1 (5.3%) |
 No information | 8 (42.1%) |
Sample size | |
  < 250 | 2 (10.5%) |
 250–499 | 4 (21.1%) |
 500–749 | 4 (21.1%) |
 750–1000 | 3 (15.8%) |
  > 1000 | 6 (31.6%) |
Screening method | |
 Pap smear/cytology-based | 6 (31.6%) |
 Visual inspection | 3 (15.8%) |
 HPV DNA testing | 1 (5.3%) |
 Multiple methods | 4 (21.1%) |
 No information | 5 (26.3%) |
Minimum eligible screening age, in years | |
  < 18 | 1 (5.3%) |
 18–24 | 5 (26.3%) |
 25–29 | 3 (15.8%) |
 30–34 | 4 (21.1%) |
 35+ | 1 (5.3%) |
 No information | 5 (26.3%) |